Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations (2020 - 2021)

Agios Pharmaceuticals (AGIO) has disclosed Cash from Discontinued Operations for 2 consecutive years, with 4102000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Cash from Discontinued Operations fell 335.48% year-over-year to 4102000.0, compared with a TTM value of 4102000.0 through Sep 2022, up 95.31%, and an annual FY2021 reading of 93234000.0, down 99.15% over the prior year.
  • Cash from Discontinued Operations was 4102000.0 for Q4 2021 at Agios Pharmaceuticals, up from 10318000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 1742000.0 in Q4 2020 and bottomed at 48291000.0 in Q2 2021.